Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 5, pp 1176–1183 | Cite as

Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study

  • In-Hwan Kim
  • Sung-Soo Park
  • Chang-Min Lee
  • Min Chan Kim
  • In-Kyu Kwon
  • Jae-Seok Min
  • Hyoung-Il Kim
  • Han Hong Lee
  • Sang-Il Lee
  • Hyundong Chae
Gastrointestinal Oncology

Abstract

Background

After curative resection of gastric cancer with D2 lymph node dissection, postoperative adjuvant chemotherapy with S-1 or capecitabine plus oxaliplatin (XELOX) is considered to be standard therapy in Eastern countries. This study aimed to compare the efficacies of adjuvant S-1 and XELOX chemotherapy for gastric cancer patients after D2 dissection based on disease-free survival (DFS).

Methods

This retrospective observational study was conducted at 29 tertiary hospitals in Korea. Of 1898 patients who underwent curative resection and received adjuvant chemotherapy for gastric cancer between February 2012 and December 2013, 1088 patients who met the eligibility criteria were enrolled in the study. After propensity score-matching, the 3-year disease-free survival rate (DFS) was used to compare efficacies directly between adjuvant XELOX and S-1 chemotherapies for patients with stage 2 or 3 gastric cancer after D2 gastrectomy.

Results

The 3-year DFS rates for the S-1 and XELOX groups did not differ significantly among disease stages 2A, 2B, and 3A (all p > 0.05). However, the survival rates for the S-1 group were significantly lower than for the XELOX group for stage 3B (65.8% vs. 68.6%; p = 0.019) and stage 3C (48.4% vs. 66.7%; p = 0.002) gastric cancer. The hazard ratios (HRs) of S-1 chemotherapy for recurrence compared with XELOX for stages 3B and 3C were respectively 2.030 [95% confidence interval (CI), 1.110–3.715; p = 0.022] and 2.732 (95% CI 1.427–5.234; p = 0.002).

Conclusions

Adjuvant XELOX chemotherapy was more effective than S-1 for patients with stage 3B or 3C gastric cancer after D2 lymph node dissection.

Notes

Acknowledgment

We especially thank Wan-Sik Yu, MD, Oh-Kyung Kwon, MD, Seung-Su Lee, MD, Sang-Eok Lee, MD, Young-Jun Lee, MD, Sang-Ho Jung, MD, Sung-Il Choi, MD, Seung-Wan Ryu, MD, Jong-Seok Kim, MD, Seong-Heum Park, MD, Jong-Han Kim, MD, Ye-Seob Ji, MD, Il-Myoung Kim, MD, Soon-Hwi Hwang, MD, Jun-Hyun Lee, MD, Do-Joog Park, MD, Moon-Won Yu, MD, Sang-Uk Han, MD, Yong-Kwan Jo, MD, Hang-Jong Yu, MD, Jong-In Lee, MD, Sung-Ho Jin, MD, Jin-Jo Kim, MD, Seung-Man Park, MD, Sung-Su Kim, MD, Joong-Min Park, MD, Min-Kyu Kim, MD, and all members of the Surgical Oncology Forum (SOF) of Korea for collaboration, discussion, and data-sharing for this study.

References

  1. 1.
    Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Modern surgery for gastric cancer: Japanese perspective. Scand J Surg. 2006;95:232–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol. 2006;12:3237–42.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gunderson LL. Gastric cancer-patterns of relapse after surgical resection. Semin Radiat Oncol. 2002;12:150–61.CrossRefPubMedGoogle Scholar
  4. 4.
    Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Nakajima T. Review of adjuvant chemotherapy for gastric cancer. World J Surg. 1995;19:570–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer. 2005;8:78–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002;9:278–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRefGoogle Scholar
  18. 18.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79:1522–30.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.CrossRefPubMedGoogle Scholar
  21. 21.
    Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMedGoogle Scholar
  22. 22.
    Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Randle RW, Swords DS, Levine EA, et al. Optimal extent of lymphadenectomy for gastric adenocarcinoma: a 7-institution study of the U.S. gastric cancer collaborative. J Surg Oncol. 2016;113:750–5.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.CrossRefPubMedGoogle Scholar
  25. 25.
    Fuse N, Bando H, Chin K, et al. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer. 2017;20:332–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2013;11:531–46.CrossRefPubMedGoogle Scholar
  27. 27.
    Takahari D, Hamaguchi T, Yoshimura K, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Kodera Y, Ishiyama A, Yoshikawa T, et al. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer. 2010;13:197–203.CrossRefPubMedGoogle Scholar
  29. 29.
    Hu X, Chen L, Du Y, et al. Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial. Chin J Cancer Res. 2017;29:144–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Deng J, Liang H, Wang D, Sun D, Pan Y, Liu Y. Investigation of the recurrence patterns of gastric cancer following a curative resection. Surg Today. 2011;41:210–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2010;21:50–4.CrossRefGoogle Scholar
  32. 32.
    Inaki N, Etoh T, Ohyama T, et al. A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg. 2015;39:2734–41.CrossRefPubMedGoogle Scholar
  33. 33.
    Hur H, Lee HY, Lee HJ, et al. Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer. 2015;15:355.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol. 2016;34:1350–7.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • In-Hwan Kim
    • 1
  • Sung-Soo Park
    • 2
  • Chang-Min Lee
    • 2
  • Min Chan Kim
    • 3
  • In-Kyu Kwon
    • 4
  • Jae-Seok Min
    • 5
  • Hyoung-Il Kim
    • 6
  • Han Hong Lee
    • 7
  • Sang-Il Lee
    • 8
  • Hyundong Chae
    • 1
  1. 1.Department of SurgeryDaegu Catholic University School of MedicineDaeguSouth Korea
  2. 2.Department of SurgeryKorea University College of Medicine and School of MedicineSeoulSouth Korea
  3. 3.Department of SurgeryDong-A University School of MedicineBusanSouth Korea
  4. 4.Department of SurgeryKeimyung University School of MedicineDaeguSouth Korea
  5. 5.Department of SurgeryDongnam Institute of Radiological and Medical SciencesBusanSouth Korea
  6. 6.Department of SurgeryYonsei University School of MedicineSeoulSouth Korea
  7. 7.Department of SurgerySeoul St. Mary’s HospitalSeoulSouth Korea
  8. 8.Department of SurgeryChungnam National University School of MedicineDaejeonSouth Korea

Personalised recommendations